GTBP insider filings
GT Biopharma, Inc. — 29 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-09-08. Screen GTBP transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for GTBP between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — GT Biopharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-09-08 | 4 | URBAN ALAN LOUIS — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-09-08 | 4 | Mun-Gavin David C. — Director | Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2025-09-08 | 4 | Kramer Hilary — Director | Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2025-09-08 | 4 | CASAMENTO CHARLES J — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2025-09-08 | 4 | Breen Michael Martin — CEO and Director, Director | Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-10-21 | 4 | URBAN ALAN LOUIS — Chief Financial Officer | Grant/award (A): 23,335 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | Breen Michael Martin — Executive Chairman/Interim CEO, Director | Grant/award (A): 200,000 @ $0.29 | EDGAR |
| 2023-08-15 | 4 | Ohri Manu — CFO & Secretary | Grant/award (A): 200,000 @ $0.29 · Other (J): 200,000 @ $0.29 · Other (J): 200,000 @ $0.29 | EDGAR |
| 2023-06-21 | 4 | CASAMENTO CHARLES J — Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2023-04-11 | 4 | Breen Michael Martin — Executive Chairman/Interim CEO, Director | Purchase (P): 50,000 @ $0.50 | EDGAR |
| 2023-04-10 | 4 | Ohri Manu — CFO & Secretary | Purchase (P): 50,000 @ $0.50 | EDGAR |
| 2023-02-01 | 4 | Breen Michael Martin — Exec Chairman and Interim CEO, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2023-02-01 | 4 | Ohri Manu — Chief Financial Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2023-02-01 | 4 | SHROTRIYA RAJESH C MD — Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2023-02-01 | 4 | Wendel Bruce — Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2022-07-19 | 4 | Breen Michael Martin — Exec. Chair. and Interim CEO, Director | Grant/award (A): 278,058 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-07-19 | 4 | SHROTRIYA RAJESH C MD — Director | Grant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 361,476 (derivative) @ $0 | EDGAR |
| 2022-07-19 | 4 | URBAN ALAN LOUIS — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-07-19 | 4 | Berk Gregory — Pres. of R&D, CMO | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-07-19 | 4 | Ohri Manu — CFO & Secretary | Grant/award (A): 100,000 @ $0 · Other (J): 100,000 @ $0 · Other (J): 100,000 @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2022-07-19 | 4 | Wendel Bruce — Director | Grant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-02-14 | 4 | Berk Gregory — Director | Grant/award (A): 278,058 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-02-14 | 4 | SHROTRIYA RAJESH C MD — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-02-14 | 4 | Choy Gavin — Acting Chief Financial Officer | Grant/award (A): 227,500 (derivative) @ $0 | EDGAR |
| 2021-11-12 | 4 | Breen Michael Martin — Director | Grant/award (A): 278,058 @ $0 · Conversion (C): 40,243 @ $3.40 · Conversion (C): 9,859 @ $3.40 · Grant/award (A): 50,000 (derivative) @ $0 · Conversion (C): 100,000 (derivative) @ $0 · Conversion (C): 30,000 (derivative) @ $0 | EDGAR |
| 2021-10-07 | 4 | Wendel Bruce — Director | Purchase (P): 3,268 @ $3.14 · Purchase (P): 1,374 @ $8.87 · Purchase (P): 441 @ $8.73 · Grant/award (A): 347,572 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2020-12-23 | 4 | Weldon Steven W | Sale (S): 50,000 @ $0.30 · Sale (S): 50,000 @ $0.33 · Sale (S): 35,722 @ $0.34 · Sale (S): 47,978 @ $0.40 | EDGAR |
| 2020-12-18 | 4 | Weldon Steven W | Sale (S): 50,000 @ $0.30 · Sale (S): 50,000 @ $0.30 · Sale (S): 50,000 @ $0.31 · Sale (S): 50,000 @ $0.30 | EDGAR |
| 2020-12-15 | 4 | Weldon Steven W | Sale (S): 50,000 @ $0.25 · Sale (S): 50,000 @ $0.26 · Sale (S): 50,000 @ $0.28 · Sale (S): 50,000 @ $0.29 · Sale (S): 46,300 @ $0.29 · Sale (S): 50,000 @ $0.30 · +2 more | EDGAR |
Recent 8-K events — GT Biopharma, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-25 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-03 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-22 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-02 | 8-K | 4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — GT Biopharma, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299408 (S-1) — latest: Initial registration (S-1), filed 2026-10-09
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GTBP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs